Visitors Now:
Total Visits:
Total Stories:
Profile image
Story Views

Last Hour:
Last 24 Hours:

Vulvovaginal Candidiasis Therapeutic Pipeline Market Review, H2 2016

Friday, October 14, 2016 3:37
% of readers think this story is Fact. Add your two cents.

(Before It's News)


‘Vulvovaginal Candidiasis – Pipeline Review, H2 2016’, provides an overview of the Vulvovaginal Candidiasis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Vulvovaginal Candidiasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Vulvovaginal Candidiasis and features dormant and discontinued projects.

Request a sample report @

Report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.


- The report provides a snapshot of the global therapeutic landscape of Vulvovaginal Candidiasis 
- The report reviews pipeline therapeutics for Vulvovaginal Candidiasis by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Vulvovaginal Candidiasis therapeutics and enlists all their major and minor projects 
- The report assesses Vulvovaginal Candidiasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Vulvovaginal Candidiasis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies 
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Vulvovaginal Candidiasis 
- Identify potential new clients or partners in the target demographic 
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics 
- Devise corrective measures for pipeline projects by understanding Vulvovaginal Candidiasis pipeline depth and focus of Indication therapeutics 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope 
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Make an enquiry before buying this Report @

Key points in table of content

Table of Contents 2 
List of Tables 5 
List of Figures 5 
Introduction 6 
Global Markets Direct Report Coverage 6 
Vulvovaginal Candidiasis Overview 7 
Therapeutics Development 8 
Pipeline Products for Vulvovaginal Candidiasis – Overview 8 
Vulvovaginal Candidiasis – Therapeutics under Development by Companies 9 
Vulvovaginal Candidiasis – Pipeline Products Glance 10 
Clinical Stage Products 10 
Early Stage Products 11 
Unknown Stage Products 12 
Vulvovaginal Candidiasis – Products under Development by Companies 13 
Vulvovaginal Candidiasis – Companies Involved in Therapeutics Development 14 
Cidara Therapeutics, Inc. 14 
Grupo Ferrer Internacional, S.A. 15 
NovaDigm Therapeutics, Inc. 16 
Scynexis, Inc. 17 
TGV-Laboratories 18 
Viamet Pharmaceuticals, Inc. 19 
Vulvovaginal Candidiasis – Therapeutics Assessment 20 
Assessment by Monotherapy Products 20 
Assessment by Combination Products 21 
Assessment by Target 22 
Assessment by Mechanism of Action 24 
Assessment by Route of Administration 26 
Assessment by Molecule Type 28 
Drug Profiles 30 
(clotrimazole + diclofenac sodium) – Drug Profile 30 
Product Description 30 
Mechanism Of Action 30 
R&D Progress 30 
arasertaconazole – Drug Profile 31 
Product Description 31 
Mechanism Of Action 31 
R&D Progress 31 
CD-101 – Drug Profile 32 
Product Description 32 
Mechanism Of Action 32 
R&D Progress 32 
MH-010 – Drug Profile 35 
Product Description 35 
Mechanism Of Action 35 
R&D Progress 35 
Myc-102 – Drug Profile 36 
Product Description 36 
Mechanism Of Action 36 
R&D Progress 36 
NDV-3 – Drug Profile 37 
Product Description 37 
Mechanism Of Action 37 
R&D Progress 37 
NDV-3A – Drug Profile 39 
Product Description 39 
Mechanism Of Action 39 
R&D Progress 39 
SCY-078 – Drug Profile 40 
Product Description 40 
Mechanism Of Action 40 
R&D Progress 40 
TOL-463 – Drug Profile 43 
Product Description 43 
Mechanism Of Action 43 
R&D Progress 43 
VT-1161 – Drug Profile 44 
Product Description 44 
Mechanism Of Action 44 
R&D Progress 44 
Vulvovaginal Candidiasis – Dormant Projects 48 
Vulvovaginal Candidiasis – Discontinued Products 49 
Vulvovaginal Candidiasis – Product Development Milestones 50 
Featured News & Press Releases 50 
Aug 15, 2016: NovaDigm Therapeutics Announces Positive Results from First-ever Antifungal Immunotherapy in a Phase 2a Study in Women with Recurrent Vulvovaginal Candidiasis 50 
Aug 10, 2016: Positive Interim Clinical Results for VT-1161 to be Presented at the Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 51 
Aug 09, 2016: Cidara Therapeutics Announced Presentations Addressing Vulvovaginal Candidiasis at Upcoming IDSOG Annual Meeting 51 
Aug 08, 2016: SCYNEXIS Reports Second Quarter 2016 Financial Results and Provides Company Update 52 
Jun 09, 2016: Cidara Therapeutics Doses First Patient in Phase 2 Trial of CD101 Topical to Treat Vulvovaginal Candidiasis 53 
Jun 08, 2016: Cidara Therapeutics to Present Data on Lead Antifungal Product Candidate CD101 at Upcoming ASM Microbe 2016 54 
Jun 08, 2016: SCYNEXIS Announces Positive Results in its Proof-of-Concept Phase 2 Study of SCY-078, the First Member of a Novel Class of Glucan Synthase Inhibitors 55 
May 31, 2016: FDA Grants QIDP and Fast Track Designation to CD101 Topical, Cidara Therapeutics Novel Antifungal Product Candidate 56 
Mar 09, 2016: Viamet Reports Positive Results from Interim Analysis of REVIVE Phase 2b Trial of VT-1161 in Recurrent Vulvovaginal Candidiasis 57 
Jan 28, 2016: SCYNEXIS Receives FDA Fast Track and QIDP Designations for Intravenous Formulation of SCY-078 for the Treatment of Patients with Invasive Fungal Infections 58 
Jan 11, 2016: Cidara Therapeutics Announces Positive Data from Multiple Dose Phase 1 Clinical Trial of CD101 IV 59 
Dec 01, 2015: SCYNEXIS Initiates Enrollment of the Phase 2 Study of SCY-078 in Vulvovaginal Candidiasis 59 
Jul 29, 2015: Viamet to Present at Infectious Diseases Society for Obstetrics and Gynecology Annual Meeting 60 
Apr 24, 2015: Viamet to Provide Update on VT-1161, Novel Antifungal Program at ECCMID 2015 60 
Feb 12, 2015: Viamet Announces Initiation of REVIVE Phase 2b Study of VT-1161 in Recurrent Vulvovaginal Candidiasis 61 
Appendix 62 
Methodology 62 
Coverage 62 
Secondary Research 62 
Primary Research 62 
Expert Panel Validation 62 
Contact Us 62 
Disclaimer 63

List of Tables 
Number of Products under Development for Vulvovaginal Candidiasis, H2 2016 8 
Number of Products under Development by Companies, H2 2016 9 
Comparative Analysis by Clinical Stage Development, H2 2016 10 
Comparative Analysis by Early Stage Development, H2 2016 11 
Comparative Analysis by Unknown Stage Development, H2 2016 12 
Products under Development by Companies, H2 2016 13 
Vulvovaginal Candidiasis – Pipeline by Cidara Therapeutics, Inc., H2 2016 14 
Vulvovaginal Candidiasis – Pipeline by Grupo Ferrer Internacional, S.A., H2 2016 15 
Vulvovaginal Candidiasis – Pipeline by NovaDigm Therapeutics, Inc., H2 2016 16 
Vulvovaginal Candidiasis – Pipeline by Scynexis, Inc., H2 2016 17 
Vulvovaginal Candidiasis – Pipeline by TGV-Laboratories, H2 2016 18 
Vulvovaginal Candidiasis – Pipeline by Viamet Pharmaceuticals, Inc., H2 2016 19 
Assessment by Monotherapy Products, H2 2016 20 
Assessment by Combination Products, H2 2016 21 
Number of Products by Stage and Target, H2 2016 23 
Number of Products by Stage and Mechanism of Action, H2 2016 25 
Number of Products by Stage and Route of Administration, H2 2016 27 
Number of Products by Stage and Molecule Type, H2 2016 29 
Vulvovaginal Candidiasis – Dormant Projects, H2 2016 48 
Vulvovaginal Candidiasis – Discontinued Products, H2 2016 49

Get this report @


Contact US:


Partner Relations & Marketing Manager

Ph: +1-646-845-9349 (US)

Ph: +44 208 133 9349 (UK)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Top Stories
Recent Stories



Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.